Statistical Considerations for Clinical Trials During COVID-19: Blinded Data Review for Adaptive Estimands (Part III)

Qing Liu; Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Blinded Data Review for Adaptive Estimands (Part III)

Biostatistics, Epidemiology & Environmental Health Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

As stated early in part I of the article, the focus of this article is for moderately COVID-19 affected ongoing trials where no formal interim analysis is planned. This requires a comprehensive assessment of each attribute of an estimand affected by unplanned trial modifications due to COVID-19. In addition, a formal process for adaptive statistical analysis planning, as described by Liu and Chi (2010a) and restated below, is also required.

Original language	American English
Journal	LinkedIn
State	Published - Apr 15 2020

Disciplines

Biostatistics
Environmental Public Health
Epidemiology
Public Health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://www.linkedin.com/pulse/statistical-considerations-clinical-trials-during-data-asa-fellow-1c/

Cite this

@article{9fd493f65d9748c9b3aedf586483c9ba,

title = "Statistical Considerations for Clinical Trials During COVID-19: Blinded Data Review for Adaptive Estimands (Part III)",

abstract = " As stated early in part I of the article, the focus of this article is for moderately COVID-19 affected ongoing trials where no formal interim analysis is planned. This requires a comprehensive assessment of each attribute of an estimand affected by unplanned trial modifications due to COVID-19. In addition, a formal process for adaptive statistical analysis planning, as described by Liu and Chi (2010a) and restated below, is also required.",

author = "Qing Liu and Peace, {Karl E.}",

year = "2020",

month = apr,

day = "15",

language = "American English",

journal = "LinkedIn",

}

TY - JOUR

T1 - Statistical Considerations for Clinical Trials During COVID-19: Blinded Data Review for Adaptive Estimands (Part III)

AU - Liu, Qing

AU - Peace, Karl E.

PY - 2020/4/15

Y1 - 2020/4/15

N2 - As stated early in part I of the article, the focus of this article is for moderately COVID-19 affected ongoing trials where no formal interim analysis is planned. This requires a comprehensive assessment of each attribute of an estimand affected by unplanned trial modifications due to COVID-19. In addition, a formal process for adaptive statistical analysis planning, as described by Liu and Chi (2010a) and restated below, is also required.

AB - As stated early in part I of the article, the focus of this article is for moderately COVID-19 affected ongoing trials where no formal interim analysis is planned. This requires a comprehensive assessment of each attribute of an estimand affected by unplanned trial modifications due to COVID-19. In addition, a formal process for adaptive statistical analysis planning, as described by Liu and Chi (2010a) and restated below, is also required.

UR - https://digitalcommons.georgiasouthern.edu/bee-facpubs/145

UR - https://www.linkedin.com/pulse/statistical-considerations-clinical-trials-during-data-asa-fellow-1c/

M3 - Article

JO - LinkedIn

JF - LinkedIn

ER -

Statistical Considerations for Clinical Trials During COVID-19: Blinded Data Review for Adaptive Estimands (Part III)

Abstract

Disciplines

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this